Speciality Medicines Board of Directors

Get the latest insights into the leadership at Speciality Medicines. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Parthkumar Goyani Chairman & Managing Director
Mr. Sumit Goyani Whole Time Director
Mr. Bhaveshkumar Savani Non Executive Director
Mr. Chandresh Unagar Independent Director
Ms. Archana Bhayani Independent Director

Speciality Medicines Share price

SPML

125.9

0.00 (0.00%)
Last updated on 1 Apr, 2026 | 07:50 IST
Today's High

00

Today's Low

00

52 Week Low

124.00

52 Week High

129.50

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Speciality Medicines FAQs

The board at Speciality Medicines consists of experienced professionals, including Mr. Parthkumar Goyani , Mr. Sumit Goyani , and others, overseeing the company’s strategic and corporate governance.

Directors at Speciality Medicines are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Parthkumar Goyani is the current chairman at Speciality Medicines.

Executive directors at Speciality Medicines are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Speciality Medicines adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Speciality Medicines, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost